- Sermorelin ODT (compounded)
- From $199/month
- BPC-157, DSIP, epithalon, MOTS-c (compounded)
- From $200 to $320/month, by peptide
- FDA-approved wellness peptides offered
- None
- Starting point
- Labs and a clinician review
What peptides are
Peptides are short chains of amino acids, the same building blocks that make up proteins. Your body uses thousands of them as signals; insulin is a peptide, and so are the GLP-1 weight-loss medications semaglutide and tirzepatide. Being a peptide says nothing about whether a substance is safe or effective, just about its structure.
The peptides marketed for recovery, sleep, longevity and energy are a different group. Most have never gone through the FDA approval process, and much of what is claimed about them comes from animal studies.
An honest word first
For most wellness peptides, human evidence is thin: small studies, short follow-up and few placebo-controlled trials. Promising results in rodents often do not hold up in people. When FDA scientists reviewed BPC-157, TB-500, KPV, MOTS-c, DSIP, semax and epitalon in 2026, they concluded the available studies were insufficient to establish safety or effectiveness for the uses reviewed.
That does not mean no one benefits. It means you should approach peptides as an experiment with a defined goal, a set time frame and a willingness to stop, under a clinician's supervision rather than from an online seller.
Where FDA regulation stands in late 2026
None of the wellness peptides offered through HealifyMD is FDA-approved. In 2023 the FDA placed a number of popular peptides on a list of bulk substances raising significant safety risks for compounding. In April 2026 the agency said it intended to move a dozen peptides off that list and sent several to its Pharmacy Compounding Advisory Committee.
In July 2026 the committee narrowly voted to recommend BPC-157, TB-500, KPV, MOTS-c, epitalon and semax for the 503A bulks list, and voted against DSIP. Those votes are advisory. As of October 2026 the FDA had not completed the rulemaking needed to add any of them to the list, so their status remains under review and could change.
Find the approach that fits you
Peptides are rarely the first step. We have organized our guidance by the situations people most often bring to us:
- Athletes and active adults whose recovery has slowed.
- Women in perimenopause and menopause, where hormone therapy usually comes first.
- Busy executives and professionals dealing with low energy and poor sleep.
- Men in midlife, where testosterone is evaluated before any peptide.
Peptides you may hear about
- Sermorelin: a growth hormone–releasing hormone analog. A sermorelin product was once FDA-approved and later discontinued, not for safety or effectiveness reasons. Compounded sermorelin is not FDA-approved.
- BPC-157, TB-500 and KPV: studied mainly in animals for tissue repair and inflammation.
- MOTS-c: a peptide encoded in mitochondria, studied mainly in animals for metabolism.
- Epithalon: promoted for longevity and sleep, with very limited human data.
- DSIP: promoted for sleep; the advisory committee did not recommend it.
- PT-141 (bremelanotide): FDA-approved as Vyleesi for a specific group of premenopausal women; compounded versions are not FDA-approved.
How peptide therapy works at HealifyMD
- Measure: labs and a history to look for common, treatable causes first.
- Decide: your clinician explains the evidence and whether a peptide makes sense for your goal.
- Trial: a defined period with a clear goal, filled by a licensed pharmacy.
- Review: follow-up on benefits and side effects.
- Stop or adjust: if there is no meaningful benefit, the peptide is discontinued.
Who should avoid peptides
Peptides are not for anyone pregnant, breastfeeding or trying to conceive, or for people with active cancer, since some peptides affect growth signaling. Competitive athletes subject to drug testing should know that BPC-157 and many related peptides are prohibited. We do not provide home dosing instructions for compounded peptides; your clinician sets any dose.
